The drug, Ibrance (palbociclib), does not follow the traditional methods of treatment for postmenopausal women with ER+/HER2- metastatic breast cancer. Instead, by targeting specific proteins within the cancer cells, this “breakthrough therapy” stops the cells from dividing. This means that the cancer cells can no longer reproduce, thereby halting the growth and spread of the desease throughout the body. To read more on UCLA and Dr. Richard Finn’s study, please click the link below.

Breakthrough Therapy